Shares of Allurion Technologies Inc. (ALUR) are up over 90% at $7, following its plan to initiate a clinical study combining the Allurion Program with GLP-1 agonists to improve muscle mass and overall body composition.
The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world's first and only swallowable, procedure-less gastric balloon for weight loss, the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Balloon was commercially launched in January 2016 and is marketed in over 50 countries outside the U.S.
For comments and feedback: editorial@rttnews.com